Abstract
The efficacy of anti-angiogenic therapies on cancer patients is limited by the emergence of drug resistance, urging the search for second-generation drugs. In this study, we screened an academic chemical library (DCM, University of Grenoble-Alpes) and identified a leader molecule, COB223, that inhibits endothelial cell migration and proliferation. It inhibits also Lewis lung carcinoma (LLC/2) cell proliferation whereas it does not affect fibroblast proliferation. The anti-angiogenic activity of COB223 was confirmed using several in vitro and in vivo assays. In a mouse LLC/2 tumor model, ip administration of doses as low as 4 mg/kg COB223 efficiently reduced the tumor growth rate. We observed that COB223 inhibits endothelial cell ERK1/2 phosphorylation induced by VEGF, FGF-2 or serum and that it acts downstream of PKC and upstream of Ras. This molecule represents a novel anti-angiogenic and anti-tumorigenic agent with an original mechanism of action that deserves further development as an anti-cancer drug.
Keywords:
VEGF signaling; angiogenesis; chemical library; drug development.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antineoplastic Agents / chemical synthesis
-
Antineoplastic Agents / pharmacology*
-
Apoptosis / drug effects
-
Blotting, Western
-
Carbamates / chemical synthesis
-
Carbamates / pharmacology*
-
Carcinoma, Lewis Lung / blood supply
-
Carcinoma, Lewis Lung / pathology
-
Carcinoma, Lewis Lung / prevention & control*
-
Cell Movement / drug effects
-
Cell Proliferation / drug effects
-
Cell Transformation, Neoplastic / drug effects*
-
Cell Transformation, Neoplastic / metabolism
-
Cell Transformation, Neoplastic / pathology
-
Embryonic Stem Cells / cytology
-
Embryonic Stem Cells / drug effects
-
Embryonic Stem Cells / metabolism
-
Endothelium, Vascular / cytology
-
Endothelium, Vascular / drug effects
-
Endothelium, Vascular / metabolism
-
Fibroblasts / cytology
-
Fibroblasts / drug effects
-
Fibroblasts / metabolism
-
Gene Expression Regulation, Neoplastic / drug effects*
-
High-Throughput Screening Assays
-
Humans
-
Immunoenzyme Techniques
-
Mice
-
Mice, Inbred BALB C
-
Mice, Nude
-
Neovascularization, Pathologic / pathology
-
Neovascularization, Pathologic / prevention & control*
-
Phosphorylation / drug effects
-
Signal Transduction / drug effects
-
Skin / cytology
-
Skin / drug effects
-
Skin / metabolism
-
Sulfonamides / chemical synthesis
-
Sulfonamides / pharmacology*
-
Tumor Cells, Cultured
-
Vascular Endothelial Growth Factor A / antagonists & inhibitors*
-
Vascular Endothelial Growth Factor A / metabolism
-
Xenograft Model Antitumor Assays
-
ras Proteins / metabolism*
Substances
-
Antineoplastic Agents
-
COB223
-
Carbamates
-
Sulfonamides
-
Vascular Endothelial Growth Factor A
-
ras Proteins